AbCellera Biologics Inc. 8K

AbCellera reported statistically significant and well-tolerated Phase 2 clinical trial results for its investigational menopause treatment ABCL635, demonstrating substantial reductions in vasomotor symptoms after a single dose.

AbCellera Biologics Inc. announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial of ABCL635, an investigational NK3 receptor antagonist antibody being developed as a non-hormonal, long-acting subcutaneous treatment for moderate-to-severe vasomotor symptoms due to menopause, showing statistically significant and clinically meaningful reductions in the frequency and severity of hot flashes at week 4 after a single 600 mg dose versus placebo, along with improved sleep and patient global impression of change and a favorable tolerability profile without serious or severe adverse events or discontinuations, and the company scheduled an investor conference call and webcast on August 10, 2026 to discuss these results.

Filing Facts

CIK

1703057

Ticker

ABCL

Form

8K

Source Type

fda

Accession

0001703057-26-000053

Alert Tier

6